Read twice and referred to the Committee on Finance.
The bill creates an exception to Medicare drug price negotiations for certain "research and development-intensive small biotech manufacturers" beginning with initial price applicability year 2029. Eligible small biotech firms (five or fewer qualifying single-source drugs) that spend a defined percentage of net revenue on R&D (30%–70% depending on drug count) may exclude qualifying drugs from negotiation.
Progressives emphasize affordability and Medicare bargaining loss
Relative to its intended legislative type, this bill is a substantive policy amendment that is reasonably well-specified in its core definitions and thresholds and includes basic administrative hooks (annual application, certification, appeals, acquisition rule).
The bill creates an exception to Medicare drug price negotiations for certain "research and development-intensive small biotech manufacturers" beginning with initial price applicability year 2029.
Eligible small biotech firms (five or fewer qualifying single-source drugs) that spend a defined percentage of net revenue on R&D (30%–70% depending on drug count) may exclude qualifying drugs from negotiation.
The bill requires annual applications to the HHS Secretary with revenue and R&D documentation, allows appeal of adverse determinations, and disqualifies drugs if the manufacturer is acquired by a non-qualifying firm after 2029.
Narrow, industry‑favoring exemption lowers savings and invites opposition; could succeed if attached to larger legislation or bipartisan deal.
Relative to its intended legislative type, this bill is a substantive policy amendment that is reasonably well-specified in its core definitions and thresholds and includes basic administrative hooks (annual application, certification, appeals, acquisition rule). It lacks explicit fiscal/resourcing provisions, detailed verification and enforcement measures, and concrete administrative timelines, leaving substantial implementation detail to the Secretary.
Progressives emphasize affordability and Medicare bargaining loss
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize affordability and Medicare bargaining loss
Likely skeptical of the carve-out because it reduces Medicare’s negotiation leverage and could raise drug costs for beneficiaries.
May acknowledge support for small biotech innovation but view the bill as favoring industry over affordability.
Views the bill as a targeted incentive for small, R&D-heavy biotech firms but is concerned about fiscal impact and potential for gaming.
Would favor it with clear transparency, auditability, and time-limited safeguards.
Likely favorable, viewing the bill as reducing price-control reach and protecting small biotech innovation.
Sees it as promoting competition, entrepreneurship, and protection from heavy-handed federal negotiation.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, industry‑favoring exemption lowers savings and invites opposition; could succeed if attached to larger legislation or bipartisan deal.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize affordability and Medicare bargaining loss
Narrow, industry‑favoring exemption lowers savings and invites opposition; could succeed if attached to larger legislation or bipartisan de…
Relative to its intended legislative type, this bill is a substantive policy amendment that is reasonably well-specified in its core definitions and thresholds and includes basic administrative hooks (annual application…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.